In this article, we will be taking a look at the 5 oversold biotech stocks to invest in now. If you wish to see the complete list, visit 8 Oversold Biotech Stocks to Invest In Now.

5. Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

Price Target Upside: 378.93%  

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is among the oversold biotech stocks to invest in now.

TheFly reported on April 7 that H.C. Wainwright reduced its price target on CVKD from $32 to $13 while maintaining a Buy rating. The adjustment reflects updated assumptions around share count and financing requirements, along with the inclusion of CAD-1005 in the firm’s valuation model. The company also provided a recent update noting continued advancement of CAD-1005, including completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration to define a potential Phase 3 registrational pathway.

This analyst activity follows Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)’s March 31 announcement of its fourth-quarter and full-year 2025 financial results, which provided critical context for the updated price target, along with a corporate update on its CAD-1005 program for heparin-induced thrombocytopenia and its broader 12-LOX inhibitor platform. The company reported continued progress, including completion of an End-of-Phase 2 meeting with the U.S. FDA on March 26, 2026, to define a potential Phase 3 registrational pathway.

Phase 2 data showed fewer thrombotic events in patients receiving CAD-1005 compared to placebo, with more than a 25% absolute reduction observed on top of standard anticoagulation therapy. Research and development expenses were $0.7 million for the quarter, general and administrative expenses were $2.4 million, and net loss totaled $3.0 million. Cash and cash equivalents stood at $4.0 million, with financing options under evaluation.

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a late-stage biopharmaceutical company developing novel anticoagulant and anti-thrombotic therapies for life-threatening immune and cardiovascular conditions, including heparin-induced thrombocytopenia and chronic kidney disease-related clotting disorders.

4. Akari Therapeutics, plc (NASDAQ:AKTX)

Price Target Upside: 477.59%  

Akari Therapeutics, plc (NASDAQ:AKTX) is among the oversold stocks to invest in.

TheFly reported on April 8 that Maxim Group downgraded AKTX from Buy to Hold and did not assign a price target. The firm pointed to increased financing risk as a key concern, noting ongoing capital requirements and continued pressure on the stock following a ratio change implemented on March 31. It also highlighted a recent selloff after the company’s partnership with WuXi XDC, stating that investor sentiment has been affected by funding uncertainty. With shares trading near record lows and the company’s market value under $5 million, the firm viewed the risk profile as elevated, given a difficult capital-raising environment.

Talking about the WuXi XDC partnership, it was done on April 6. The partnership is intended to accelerate the progress of AKTX-101, the company’s lead antibody-drug conjugate program targeting metastatic urothelial cancer. PH1 is designed as a spliceosome-modulating payload that disrupts RNA splicing in cancer cells while also triggering immune system activity.

Preclinical findings have shown strong tumor reduction and instances of complete remission compared to existing ADC approaches. Akari plans to advance AKTX-101 into a Phase 1 study, with initiation expected in late 2026 or early 2027 pending regulatory clearance.

Akari Therapeutics, plc (NASDAQ:AKTX) is a clinical-stage oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) using its proprietary RNA splicing–targeting payload platform to treat solid tumors.

3. Dogwood Therapeutics, Inc. (NASDAQ:DWTX)

Price Target Upside: 713.25%  

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is one of the oversold biotech stocks on this list.

TheFly reported on April 15 that DWTX announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for SP16, an intravenous candidate being developed for chemotherapy-induced pain and peripheral neuropathy.

The therapy is designed to act through anti-inflammatory pathways by lowering cytokines such as IL-6, IL-8, IL-1β, and TNF-alpha, while also supporting tissue repair through activation of signaling proteins involved in growth and survival. The company, together with Serpin Pharma, expects enrollment in a Phase 1b trial to begin in mid-2026, with funding fully supported by a $2.5 million National Cancer Institute grant. SP16 is intended to address significant unmet needs in CIPPN, a condition affecting a large portion of chemotherapy patients and often causing long-lasting numbness, tingling, and pain.

Separately, earlier on March 18, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) reported its fourth-quarter and full-year 2025 financial performance. Research and development spending in the fourth quarter remained unchanged at $2.3 million compared with the prior year period, while general and administrative expenses declined to $1.5 million from $5.2 million due mainly to lower one-time transaction costs linked to the 2024 business combination.

The business said that its net loss for the quarter was $3.8 million, or $0.26 per share, improving from $8.2 million a year earlier. For the full year, R&D expenses rose to $21.8 million, driven largely by SP16 licensing costs and Halneuron clinical development, while net loss widened to $35.5 million. Cash totaled $6.5 million at year-end, with additional financing extending the runway into late 2026.

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is a clinical-stage biopharmaceutical company developing non-opioid therapies for pain and neuropathic disorders, including chemotherapy-induced neuropathic pain. Its lead candidate, Halneuron, targets sodium channels to reduce pain signaling.

2. Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

Price Target Upside: 1,488.24%  

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is one of the oversold stocks to invest in.

TheFly reported on April 9 that Maxim Group downgraded RVPH from Buy to Hold. The firm pointed to ongoing weakness in the share price following the company’s one-for-20 reverse stock split completed on March 9. It noted that although recent funding may help advance a second Phase 3 study of brilaroxazine, additional capital will still be required. With the stock trading below the $1.00 NASDAQ compliance level, the analyst also highlighted heightened delisting risk alongside continued financing concerns as key factors behind the downgrade.

Earlier on March 30, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) reported its full-year 2025 financial results along with key business and development updates. The company posted a net loss of approximately $19.9 million, or $5.48 per share, compared with a $29.9 million loss in 2024. Cash and cash equivalents totaled about $14.4 million as of December 31, 2025.

During 2025 and early 2026, RVPH completed multiple equity offerings, including $10.0 million raised in March 2026, with total cash expected to support operations into Q1 2027. The update also highlighted regulatory feedback from the FDA recommending a second Phase 3 trial for brilaroxazine in schizophrenia, alongside continued advancement of RECOVER-2 planned for mid-2026. Additional progress included patent expansion efforts, completed manufacturing and nonclinical studies, and ongoing

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a late-stage biopharmaceutical company developing therapies for central nervous system, inflammatory, respiratory, and cardiometabolic diseases. Its lead drug candidate, brilaroxazine, targets schizophrenia and other neuropsychiatric disorders.

1. Enlivex Ltd. (NASDAQ:ENLV)

Price Target Upside: 2,226.93% 

Enlivex Ltd. (NASDAQ:ENLV) is one of the oversold stocks to invest in now.

TheFly reported on April 7 that H.C. Wainwright increased its price target on ENLV from $13 to $20 while maintaining a Buy rating. The firm noted that the company has completed its debt financing, which is expected to provide sufficient resources to support the ongoing clinical development of its Allocetra program.

On March 23, Enlivex Ltd. (NASDAQ:ENLV) announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for Allocetra™, an immunotherapy being developed for moderate-to-severe age-related primary knee osteoarthritis. The clearance allows the company to begin a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating intra-articular injections of Allocetra in patients with the condition.

The trial is designed to assess improvements in pain, physical function, quality of life, and mobility compared with placebo at multiple time points over several months. Knee osteoarthritis affects tens of millions of patients in the United States and is expected to rise significantly over the coming decades. The company highlighted prior clinical evidence showing durable and meaningful symptom improvement lasting at least six months, particularly in older patient groups, supporting further evaluation of Allocetra as a potential treatment for this large unmet medical need.

Enlivex Ltd. (NASDAQ:ENLV) is a clinical-stage biotechnology company developing macrophage reprogramming immunotherapies, including its lead cell therapy, Allocetra, aimed at treating sepsis, osteoarthritis, and other severe inflammatory and immune-mediated diseases.

READ NEXT: 10 Best Mid Cap Stocks to Invest In According to Billionaires and 10 Best Cheap Stocks Under $10 to Buy in April.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below